The DASH trials implicate dysfunction in calcium regulation in the pathogenesis of human hypertension Alexander G. Logan Invited Commentary Pages: 367 - 370
The effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis Donald G. Vidt Clinical Trials Report Pages: 379 - 380
Meta-analyses of antihypertensive therapy: Are some of them misleading? Ehud GrossmanUri Goldbourt OriginalPaper Pages: 381 - 386
Choices and goals in the treatment of the diabetic hypertensive patient Emad BastaGeorge Bakris OriginalPaper Pages: 387 - 391
Antihypertensive therapy in pregnancy Jason G. UmansMarshall D. Lindheimer OriginalPaper Pages: 392 - 399
Using out of office blood pressure monitoring in the management of hypertension Paolo Verdecchia OriginalPaper Pages: 400 - 405
Use of gene markers to guide antihypertensive therapy Stephen T. TurnerGary L. SchwartzEric Boerwinkle OriginalPaper Pages: 410 - 415
The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue? Luis M. RuilopeCarlos CampoJulian Segura OriginalPaper Pages: 419 - 421
What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure? Murray EpsteinSheldon Tobe OriginalPaper Pages: 422 - 428
Cerebral white matter lesions in essential hypertension Cristina Sierra OriginalPaper Pages: 429 - 433
Hypertension after renal transplantation Vedat SchwengerMartin ZeierEberhard Ritz OriginalPaper Pages: 434 - 439
